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Abstract
Objectives: Erwinia asparaginase is used as a second-line formulation after a neutralizing hyper-
sensitivity reaction to the first-line formulation of asparaginase. Here, we have performed a cost-
effectiveness analysis of Erwinia asparaginase treatment.
Methods: Children with acute lymphoblastic leukemia treated according to the Dutch Childhood
Oncology ALL-10 or ALL-11 protocol were included and initially treatedwith PEGasparaginase in
the intensification phase. The total treatment costs of this treatment phase, quality of life (QoL),
and life years saved (LYS) were studied for two scenarios: (a) patients were switched to Erwinia
asparaginase treatment after a hypersensitivity reaction, or (b) asparaginase would have been
permanently stopped.
Results: Sixty-eight patients were included. There was no difference in QoL between patients
with and without a hypersensitivity reaction. The mean costs of the intensification phase per
patient were $40,925 if PEGasparaginase could be continued, $175,632 if patients had to switch
to Erwinia asparaginase, and $21,190 if asparaginase would have been permanently stopped. An
extrapolation of the literature suggests that the 5-year event-free survival would be 10.3% lower
without intensive asparaginase treatment if asparaginase is stopped after a reaction. Thus, the
costs per LYSwere $1892 for scenario 1 and $872 for scenario 2.
Conclusions: Switching to Erwinia asparaginase increases the costs per LYS by $1020, which is
modest in view of the total costs. Moreover, when asparaginase treatment can be completed by
switching to Erwinia asparaginase, relapses—and consequential costs—will be avoided. Therefore,
fromacost perspective,we recommenda switch toErwiniaasparaginase to complete asparaginase
treatment.
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1 INTRODUCTION
Asparaginase is a cornerstone of the treatment of acute lymphoblastic
leukemia (ALL) in children as adequate, intensive treatment improves
the event-free survival (EFS) significantly.1–7 However, asparaginase
treatment may be hampered by the development of hypersensitivity
reactions, generally resulting in complete neutralization of the drug.
Abbreviations: ALL, acute lymphoblastic leukemia; DCOG, Dutch ChildhoodOncology Group; EFS, event-free survival; HRQoL, health-related quality of life; HUI, Health Utilities Index; LYS, life
years saved;MAU, multiattribute utility; QALY, quality-adjusted life year; QoL, quality of life; SD, standard deviation; TDM, therapeutic drugmonitoring
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This requires a switch in formulations to maintain adequate asparag-
inase activity levels.8–10 In most developed countries, PEGasparagi-
nase is now used as a first-line formulation and Erwinia asparaginase
as a second-line formulation. The latter formulation is administered
more frequently than PEGasparaginase (three times a week instead of
every other week) due to different half-lives of the two drugs, result-
ing in a substantial increase in therapy costs.11,12 Due to increasing
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restrictions on health care resources, evaluations of costs in relation
to benefits become more important, especially for expensive drugs,
such as Erwinia asparaginase. Therefore, we have performed a cost-
effectiveness analysis in which we have compared the costs, quality of
life (QoL), and life years saved (LYS) between two scenarios: according
to scenario 1, patients were switched to Erwinia asparaginase after a
hypersensitivity reaction to PEGasparaginase. Scenario 2, which was
unethical and therefore hypothetical, described the situation in which
the asparaginase treatment was permanently stopped after a hyper-
sensitivity reaction to PEGasparaginase.
2 METHODS
2.1 Patients
The studywasperformed in theSophiaChildren'sHospital, Rotterdam,
The Netherlands and the VU University Medical Center, Amsterdam,
The Netherlands. Patients were enrolled prospectively between May
2012 and October 2016 and were treated according to the medium-
risk group of the Dutch Childhood Oncology Group (DCOG) ALL-10
(until April 2012) or the consecutive ALL-11 protocol. The study was
approved by the Institutional Review Board. Informed consent was
obtained from children >12 years old, parents or children's guardians
in accordance with the Declaration of Helsinki.
2.2 Treatment protocols
In this study, the treatment costs of the intensification phase, which
contained the majority of the asparaginase doses and hypersensitiv-
ity reactions to PEGasparaginase, were calculated. According to ALL-
10, patients were treated with native Escherichia coli asparaginase
(eight intravenous doses of 5000 IU/m2) in the induction phase, and
15 doses of PEGasparaginase (2500 IU/m2, biweekly, intravenous) in
the intensification phase. According to ALL-11, patients were treated
with PEGasparaginase in both induction (three intravenous doses,
1500 IU/m2) and the intensification phase (14 intravenous doses,
biweekly). In this protocol, therapeutic drug monitoring (TDM) was
used to individualize the doses in the intensification phase based
on asparaginase activity levels. In case of a hypersensitivity reac-
tion, defined as an allergy to or silent inactivation of PEGasparagi-
nase, patients were switched to Erwinia asparaginase (20,000 IU/m2,
three times a week). According to ALL-11, the Erwinia asparaginase
dose and/or dosing schedule was individualized to ensure adequate
asparaginase activity levels. Table 1 describes an overview of the first
30weeks of the ALL intensification therapy for ALL-10 and ALL-11.
2.3 Costs data
The direct medical costs of the intensification phase were retrospec-
tively obtained and calculated from a Dutch hospital perspective.13
All costs were converted to US dollars according to the average cur-
rency exchange rate of 2015 (€1 = $1.067). The costs included were
costs for (a) PEGasparaginase ($1387 for one vial of 3750 IU) and
Erwiniaasparaginase ($850 foronevial of 10,000 IU), rounded towhole
vials to take into account the waste; (b) chemotherapy other than
TABLE 1 Intensification of the DCOGALL-10 and ALL-11
treatment protocols
Intensification
(30weeks) DCOGALL-10 DCOGALL-11
Dexamethasone 6mg/m2/day orally
Days 0–4, every
3weeks, starting in
week 1
6mg/m2/day orally
Days 0–4, every
3weeks, starting at
week 1
Vincristine 2mg/m2/dose
intravenously
Every 3weeks,
starting in week 1
2mg/m2/dose
intravenously
Every 3weeks,
starting in week 1
Doxorubicin 30mg/m2/dose
intravenously
Weeks 1, 4, 7, 10, 13,
16
30mg/m2/dose
intravenously
Weeks 1, 4, 7, 10
Not in case of a
TEL/AML1
translocation or
Down syndrome
patients without a
IKZF1 deletion
Methotrexate 30mg/m2/ dose
intravenously
1x/week, weeks
20–30
30mg/m2/ dose
intravenously
1x/week, weeks
13–30
PEGasparaginase 2500 IU/m2
intravenously
Biweekly, weeks 1–29
Dose adjusted based
on asparaginase
activity levels
Biweekly, weeks 1–27
6-Mercaptopurine 50mg/m2/day orally
Courses of 2 weeks
starting in weeks 1,
4, 7, 10, 13, 16
Daily fromweeks
19–30
50mg/m2/day orally
Courses of 2 weeks
starting in weeks 1,
4, 7, 10
Daily fromweeks
13–30
Intrathecal
methotrexate,
cytarabine, and
prednisolone
Methotrexate
8–12mg
Cytarabine 20–30mg
Prednisolone
8–12mg
Weeks 1 and 19
Methotrexate
8–12mg
Cytarabine 20–30mg
Prednisolone
8–12mg
Weeks 1 and 19
asparaginase; (c) supportive care medication; (d) outpatient clinic vis-
its ($175 per visit in an academic hospital, $85 in a satellite hospi-
tal); (e) day care admissions; (f) inpatient days ($689 per day in an aca-
demic hospital, $476 in a satellite hospital); (g) intensive care unit days
($2163 per day); (h) blood products, (i) laboratory tests; (j) surgical
procedure costs (mainly for bone marrow punctures performed under
complete anesthesia); and (k) TDMcosts ($105, including asparaginase
activity level measurements and the formulation of dosing advices12).
The costs described included costs for staff, materials used, nutrition,
and overhead. Data were adapted from the medical files of the Eras-
musMC Rotterdam and the VU University Medical Center. Dutch tar-
iffs (index year 2015) retrieved from the Dutch Healthcare Authority
or the hospitals were used for the unit prices.14 Costswere discounted
by 4% per year to account for the time value of money in accordance
with Dutch guidelines.14
To calculate the costs of scenario 2 for the patients with a hyper-
sensitivity reaction, the number of outpatient clinic visits was assumed
to be equal to the median number of visits of patients without a
reaction. In addition, in these patients, the day care admissions for
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Erwinia asparaginase administration only were excluded. And finally,
for ALL-11 patients with a hypersensitivity reaction, only the TDM
costs that were part of the PEGasparaginase treatment were included.
2.4 Effects data
To assess the health-related quality of life (HRQoL), the Health Util-
ities Index (HUI) survey version 3.015 was completed by the patient
and/or parents in weeks 1, 3, 4 (in case of a hypersensitivity reac-
tion), and 19 of the intensification phase. The questionnaire included
10 general attributes (vision, hearing, speech, emotion, pain, ambula-
tion, dexterity, cognition, caretaking, and health) each with five or six
levels, describing a patient's health state. The single-attribute utility
and multiattribute utility (MAU) scores were calculated, representing
the HRQoL for each attribute and overall, respectively. In order to cal-
culate the quality-adjusted life years (QALYs), the MAU scores were
multiplied by the total duration of the treatment phase (30weeks).
Beside the validated HUI questions, several extra questions about
the impact of an allergic reaction and change in dosing schedule were
added to the questionnaire. These questions were not validated and,
therefore, could not be quantified as part of the HUI analysis.
The number of LYS was calculated using the EFS described in lit-
erature to indicate the difference in EFS between intensified and
less intensified asparaginase treatment: a systematic search was per-
formed to find trials studying the effect of intensified asparaginase
treatment. Next, a weighted mean difference of the EFS of patients
with andwithout intensified asparaginase treatmentwas calculated by
multiplying the difference in EFS reportedwith the number of patients
included in the study, and dividing this by the total number of patients.
In our study, patients who were switched to Erwinia asparaginase
after a hypersensitivity reaction to PEGasparaginase were considered
to have the same prognosis as patients without an allergy as they were
still intensively treated with asparaginase.16 Because the inclusion of
the ALL-10 protocol has been completed, the EFS of this protocol was
used for these patients.5
All hypersensitivity reactions occurred during the first or sec-
ond PEGasparaginase dose in intensification. Therefore, not switch-
ing would have resulted in a worse prognosis, similar to ALL treat-
ment without asparaginase treatment during intensification. Hence,
for the patients with a hypersensitivity reaction in whom, according
to scenario 2, the asparaginase therapy would have been permanently
stopped, we have subtracted the weighted mean difference in EFS
reported in the literature, from the EFS of ALL-10.5
Both theQALYs and thenumber of LYSwerediscountedby1.5%per
year to account for the value of time, according to Dutch guidelines.14
Thus, it is taken into account that LYS in the future are considered as
less valuable than LYS today.
2.5 Statistical analysis
Data were analyzed with SPSS Statistics version 21.0 (IBM Cor-
poration, Armonk, New York, USA) and MS Excel 2013 (Microsoft
Corporation, Redmond, WA, USA). Multiple imputation was used to
impute missing data. t-Tests, 𝜒2-tests or Mann-Whitney U-tests were
used to calculate the differences between the patients with and with-
out a hypersensitivity reaction, and the two scenarios. The QoL was
longitudinally analyzed using generalized estimating equations. A two-
sided p-value of <0.05 was considered statistically different. Data are
presented as frequency, median, mean, and standard deviation (SD)
when appropriate.
2.6 Decision tree analysis
A decision tree model was developed in order to compare the costs
and effects of scenario 1, which included a switch to Erwinia asparag-
inase after a hypersensitivity reaction to PEGasparaginase, to scenario
2, in which the asparaginase therapy was permanently stopped after
a hypersensitivity reaction to PEGasparaginase (Figure 1). The mean
costs per patient of the intensification phase and the LYS for patients
with and without a hypersensitivity reaction were calculated for both
scenarios andmultiplied by the probability of developing a hypersensi-
tivity reaction. Next, the costs per LYS were calculated by dividing the
total costs by the number of LYS.
2.7 Sensitivity analysis
To account for uncertainty in the calculated costs per LYS, a one-way
sensitivity analysis was performed. For this, the costs per LYS were
calculated by varying the probability of developing a hypersensitivity
reaction with the 95% confidence interval, and the mean total costs
of the intensification phase with 1 SD for all cost categories. The EFS
for patientswhowould stop asparaginase therapywas varied using the
minimal and maximal differences in EFS for intensive and no intensive
asparaginase treatment reported.
3 RESULTS
3.1 Patient characteristics
Table 2 describes the patient characteristics. In total, 68 patients were
included in the study. Of these patients, 19 (27.9%) have developed
a hypersensitivity reaction to PEGasparaginase. Most patients who
developed a hypersensitivity reaction were treated according to the
ALL-10 protocol. ALL-11 has a lower risk of hypersensitivity reactions
because in the induction phase of this protocol, PEGasparaginase was
used instead of native E. coli asparaginase. All allergies occurred dur-
ing the first or second PEGasparaginase dose of the intensification
phase. Theage, gender, andbody surface areadidnot statistically differ
between the patients with andwithout a hypersensitivity reaction.
3.2 Cost analysis
Table 3 describes the mean costs of the intensification phase for the
patients with and without a hypersensitivity reaction, for the differ-
ent scenarios. The mean total costs per patient were $40,925 with-
out a hypersensitivity reaction to PEGasparaginase, $175,632 when
patients were switched to Erwinia asparaginase, and $21,190 if the
asparaginase therapy was permanently stopped after a reaction. The
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F IGURE 1 In this figure, the costs and life years saved are calculated for each scenario. The HRQoL did not differ between patients with and
without a hypersensitivity reaction andwas, therefore, not included in this analysis. Patients were switched to Erwinia asparaginase after a
hypersensitivity reaction according to scenario 1; asparaginase treatment was permanently stopped after a hypersensitivity reaction according to
scenario 2. The Dutch life expectancy in 2015was 81.9 years, mean age at start intensification was 8.4 years. The life years savedwere discounted
with 1.5% per year. Themean costs and life year savedweremultiplied by the probabilities of each branch and summed up to calculate the totals
for each scenario. By dividing themean total costs by the total number of life years saved, the costs per life year savedwere calculated
TABLE 2 Patient characteristics
Total study group
No hypersensitivity
reaction to PEGasp
Hypersensitivity
reaction to
PEGasp
N= 68 N= 49 N= 19 p-Value
Hypersensitivity reaction (%; 95%CI) 28% (17–39%) – – –
Treatment protocol (%) ALL-10 (95%CI) 57% (46–69%) 47% (33–61%) 84% (67–100%) 0.006
Sex, %male (95%CI) 52% (40–64%) 49% (35–63%) 58% (35–81%) 0.594
Age at start intensification (years), median (IQR) 7.6 (4.8–11.6) 6.9 (4.3–11.4) 8.8 (5.4–12.9) 0.232
BSA start intensification (m2), median (IQR) 0.92 (0.73–1.35) 0.87 (0.69–1.30) 1.03 (0.81–1.44) 0.194
95%CI, 95% confidential interval; BSA, body surface area; IQR, interquartile range; PEGasp, PEGasparaginase; SD, standard deviation.
mean total drug costs for Erwinia asparaginase were $126,831, which
corresponds with 149 vials of Erwinia asparaginase. The costs of the
drug asparaginase itself accounted for 44.1%, 74.5%, and 19.2% of
the total treatment costs of the intensification phase for the three
groups, respectively. The percentage of costs for asparaginase use for
the total study cohort was 63.0% of the total intensification phase
costs. Because TDMwas only implemented in the DCOG ALL-11 pro-
tocol, the total TDM costs per patient are relatively low in this cohort.
3.3 Effects analysis
Cross-sectional analyses showed that the QALYs of the patients
with and without hypersensitivity did not differ significantly for the
questionnaires completed in intensification weeks 1, 3, and 19. The
longitudinal analysis showed that the MAU score overall decreased
with 0.12points per timepoint of the questionnaire (p<0.001), but the
occurrence of a hypersensitivity analysis was not a significant covari-
ate. Thus, the development of a hypersensitivity reaction did not result
in a significant change in the HRQoL. Therefore, this analysis was not
further included in the decision tree analysis.
Analysis of the extra questions about the burden of the aller-
gic reaction and of switching to Erwinia asparaginase is described
in Tables 4 and 5. The question about the burden of (potentially)
switching to Erwinia asparaginase was answered by both patients who
were switched to Erwinia asparaginase and patients without a hyper-
sensitivity reaction (Table 4). There was no statistically significant
difference between the scores of both groups at all time points, includ-
ing week 19, when all patients with a hypersensitivity reaction had
been switched. At these time points, patients considered switching to
Erwinia asparaginase as "no to partially a problem." In patients who did
experience an allergic reaction, the reaction was described as severe,
resulting in severe illness andmajor discomfort during the reaction.
The 5-year EFS of the medium-risk group of the DCOG ALL-10
protocol was 88.0% (standard error 2.0%).5 The EFS of the ALL-11
protocol is not available yet since the protocol is still ongoing. The
studies that have reported the effect of asparaginase therapy are
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TABLE 3 Total costs per patient of the intensification phase for the different scenarios
1. No hypersensitivity
reaction to
PEGasparaginase
2. Switch after a
hypersensitivity reaction to
PEGasparaginase
3. Stop asparaginase
after a hypersensitivity
reaction to
PEGasparaginase
Costs ($) Mean± SD (median) Mean± SD (median) Mean± SD (median)
p-Value
1 vs 2
p-Value
1 vs 3
Outpatient treatment 4201± 723 (4363) 6567± 1912 (6282) 4373± 0 (4372) <0.001 -
Day care treatment 8058± 1714 (7884) 27,541± 8611 (27,389) 2686± 376 (2905) <0.001 <0.001
Inpatient care (aca) 2942± 5033 (0) 2858± 5094 (687) 2858± 5094 (687) 0.988 0.988
Intensive care unit
admission (aca)
992± 5908 (0) 0 0 0.274 0.274
Outpatient treatment
(sat)
20± 40 (0) 14± 41 (0) 14± 41 (0) 0.507 0.507
Inpatient care (sat) 97± 307 (0) 75± 180 (0) 75± 181 (0) 0.923 0.923
PEGasparaginase 18,032± 2382 (19,360) 4076± 4527 (2766) 4076± 4527 (2766) <0.001 <0.001
Erwinia asparaginase 0± 0 (0) 126,831± 51,067 (117,054) 0 <0.001 -
TDM 865± 845 (1466) 600± 1469 (0) 50± 123 (0) 0.041 0.001
Blood products 363± 547 (215) 283± 517 (0) 283± 517 (0) 0.288 0.288
Laboratory activities 1299± 1028 (1011) 2077± 1361 (1512) 2077± 1361 (1512) 0.004 0.004
Surgical procedure costs 567± 41 (572) 557± 66 (572) 557± 66 (572) 0.118 0.118
Chemotherapy other
than asparaginase
2077± 910 (1944) 2203± 714 (2308) 2203± 714 (2308) 0.448 0.448
Supportive care
medication
1411± 1581 (990) 1948± 2325 (1922) 1948± 2325 (1922) 0.197 0.197
Total costs 40,925± 10,334
(39,671)
175,632± 58,765 (174,446) 21,190± 7221 (19,687) <0.001 <0.001
aca, academic hospital; sat, satellite hospital; SD, standard deviation; TDM, therapeutic drugmonitoring.
TABLE 4 The burden of switching to Erwinia asparaginase
Week 1a Week 3a Week 4a Week 19a
Mean± SD, median (IQR) Mean± SD, median (IQR) Mean± SD, median (IQR) Mean± SD, median (IQR)
Allergy 1.43± 0.65, 1.00 (1.00–2.00) 1.35± 0.61, 1.00 (1.00–2.00) 1.36± 0.63, 1.00 (1.00–2.00) 2.00± 1.18, 2.00 (1.00–3.00)
No allergy 2.11± 1.24, 2.00 (1.00–3.50) 2.05± 1.24, 1.00 (1.00–3.00) - 2.09± 1.16, 2.00 (1.00–3.00)
IQR, interquartile range; SD, standard deviation.
Scoring system: 1. switching to Erwinia asparaginase would not be a problem; 2. switching to Erwinia asparaginase would partially a problem; 3. switching to
Erwinia asparaginase would be a growing problem; 4. switching to Erwinia asparaginase would be amajor problem.
aThere was no statistically significant difference between themedian scores of patients with andwithout an allergic reaction.
TABLE 5 Experience of the allergy
Week 1 Week 3 Week 4 Week 19
Mean± SD,median (IQR) Mean± SD,median (IQR) Mean± SD,median (IQR) Mean± SD,median (IQR)
Severity of the allergic
reactiona
1.50± 0.67, 1.00
(1.00–2.00)
2.75± 1.76, 2.00
(1.00–5.00)
4.55± 1.21, 5.00
(5.00–5.00)
4.31± 1.49, 5.00
(4.50–5.00)
Extent of physical illness
during the allergic
reactiona
1.08± 0.29, 1.00
(1.00–1.00)
2.33± 1.83, 1.00
(1.00–4.75)
4.36± 1.21, 5.00
(4.00–5.00)
4.38± 1.50, 5.00
(5.00–5.00)
Extent of discomfort
during the allergic
reactiona
1.17± 0.58, 1.00
(1.00–1.00)
2.25± 1.66, 1.00
(1.00–3.75)
4.18± 1.40, 5.00
(4.00–5.00)
4.15± 1.52, 5.00
(3.50–5.00)
IQR, interquartile range; SD, standard deviation.
Scoring system:
Severity of the allergic-reaction: 1. not applicable; 2. no allergic reaction; 3. minor allergic reaction; 4. moderate allergic reaction; 5. severe allergic reaction.
Extent of physical illness during the allergic reaction: 1. not applicable; 2. not ill; 3. minimally ill; 4. moderately ill; 5. severely ill.
Extent of discomfort during the allergic reaction: 1. not applicable; 2. no discomfort; 3. minimal discomfort, hampering of activities; 4. moderate discomfort,
hampering some activities; 5. major discomfort, hamperingmost activities.
aPatients who had inactivation of PEGasparaginase without clinical symptoms of an allergy (silent inactivation) were excluded from this analysis (n= 14).
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described in Supplemental Results S1. The weighted mean of the
differences in 5-year EFS reported is 10.3% (range 3.3-17.0%).1–4,6,7
Of note, this percentage is an indication of the actual difference in EFS.
Thus, the 5-year EFS was assumed to be 88.0% for patients without a
hypersensitivity reaction to PEGasparaginase and patients who were
switched to Erwinia asparaginase, and assumed to be 77.7% (88.0%
minus 10.3%) when asparaginase would have been permanently
stopped. The life expectancy of patients without an event, probably
will not differ between the groups. Therefore, if patients had no event
within 5 years, their life expectancy was assumed to be equal to the
normal population for both groups. However, possible late effects of
the ALL treatment could not be taken into account. The mean overall
Dutch life expectancy in 2015 was 81.9 years17; the mean age of this
study population at start of intensification was 8.4 years. Therefore,
on average, 73.5 years (81.9 minus 8.4 years) would be saved if the
EFS would have been 100%. The EFS was 77.7% if asparaginase would
have been permanently stopped after a hypersensitivity reaction so,
in this case, the mean number of LYS would have been 57.1 years
(77.7% of 73.5 years; discounted by 1.5% per year to account for the
value of time, 38.5 years). If patients were treated intensively with
asparaginase, the EFSwas 88.0%, so themean number of LYSwas 64.7
years (88.0% of 73.5 years; discounted, 41.5 years).
3.4 Decision tree analysis
Figure 1 shows the decision tree of the two scenarios including the
costs and LYS. Taking into account the probability of developing a
hypersensitivity reaction to PEGasparaginase, the total costs of sce-
nario 1 were $78,508 versus $35,419 of scenario 2. The discounted
numbers of LYS were 41.5 for scenario 1 and 40.6 for scenario 2. Thus,
the costs per LYS were $1892 if patients were switched to Erwinia
asparaginase after a hypersensitivity reaction and $872 if asparagi-
nase would have been stopped permanently.
3.5 Sensitivity analysis
In Supplemental Figure S1, the costs per LYS are shown, varying the
probability of developing a hypersensitivity reaction (95% confidence
interval), the total treatment costs (±1 SD for all cost categories),
and EFS for patients who would have stopped with their asparaginase
treatment (variation in EFSdifferences, reported in the literature). This
one-way sensitivity analysis shows thatmainly the treatment costs and
probability of a hypersensitivity reaction influence the costs per LYS
for each scenario.
4 DISCUSSION
In this cost-effectiveness analysis of Erwinia asparaginase, we have
studied the costs of ALL intensification therapy, the HRQoL during
asparaginase treatment, and the amount of LYS for two scenarios.
According to these scenarios, patients were either switched to Erwinia
asparaginase after a hypersensitivity reaction to PEGasparaginase or
asparaginase therapy would have been permanently stopped when
the reaction occurred. The HRQoL was studied using validated HUI-
questionnaires and did not significantly differ between patients with
and without a hypersensitivity reaction, although this could possi-
bly be addressed by the relatively small number of patients. Also the
extra questions, added to specifically study the burden of switching to
Erwinia asparaginase, did not show a significant impact. Therefore, the
decision tree analysis only included the costs and LYS.
Switching to Erwinia asparaginase would cost $1020 more per LYS
than permanently stopping asparaginase treatment after a hyper-
sensitivity reaction to PEGasparaginase. Eichler et al have reviewed
cost-effectiveness thresholds reporting different maximal costs per
LYS, for example $93,500 as “rule of thumb” in the United States.18
Although our study has been performed in the Netherlands and the
threshold apply to adult patients, with an increase of $1020 per LYS
for switching to Erwinia asparaginase, the costs per LYS remain far
below these costs, andwould be acceptable. Still, it has to be taken into
account that health care costs vary considerably between countries
hampering the generalizability of this study.
However, the actual costs per LYS may vary for different reasons:
first, the actual costs per LYS for patients who would stop asparagi-
nase may be higher. Less asparaginase exposure will not only result
in a higher mortality, but also in a higher relapse rate. Ideally, these
costs would have been considered in the sensitivity analysis, but cost
data from relapse patientswere not available. Kaul et al report a three-
fold increase in costs when patients experience a relapse compared to
no relapse, although actual costs of pediatric relapse therapy have not
beendescribed.19 Hence, switching toErwiniaasparaginasewould save
more future costs.
Second, our treatment protocol contains relatively many asparagi-
nase doses and, consequently, many Erwinia asparaginase doses in case
of a hypersensitivity reaction, which increases the total intensification
costs tremendously. For treatment protocols with less asparaginase
doses, switching to Erwinia asparaginase will have less impact on the
costs, and the difference in total costs between permanently stopping
asparaginase and switching to Erwinia asparaginase will be smaller.
Third, the incidence of hypersensitivity reactions influences the
costs per LYS for both scenarios: a lower incidence will result in lower
costs per LYS in scenario 1, due to less Erwinia asparaginase use, but
also in higher costs per LYS in scenario 2 as more patients will com-
plete their asparaginase treatment. Most patients in our cohort were
treated with native E. coli asparaginase in induction (ALL-10), which
increases the risk of developing a hypersensitivity reaction. Nowadays,
most treatment protocols, including the DCOG ALL-11 protocol, use
only the less immunogenic PEGasparaginase, decreasing the number
of reactions significantly. Thus, the difference in costs per LYS between
the two scenarios will be even smaller.
Finally, to evaluate the number of LYS, we have used the EFS of the
ALL-10 protocol for the patients who completed their asparaginase
treatment. For the patients in scenario 2, in which asparaginase would
have been permanently stopped after a hypersensitivity reaction, the
EFSwas calculated by subtracting the difference in EFSbetween inten-
sive and no intensive asparaginase reported in the literature, from the
EFS of ALL-10. One might question the accuracy of this difference as
it is based on former treatment protocols. Ideally, the impact of less
asparaginase exposure in our patients should be studied within the
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treatment protocol used. However, this would be unethical to study so
the difference in EFS used is the best available evidence. Besides, the
sensitivity analysis showed that varying the EFSonly has aminor effect
on the costs per LYS as the costs barely changedwhen the difference in
EFS between intensive and less intensive asparaginase treatment was
varied between 3.3% and 17.0%.
In conclusion, according to this analysis, the costs per LYS will be
higher when patients switch to Erwinia asparaginase after a hypersen-
sitivity reaction toPEGasparaginase. However, these costs are only 1%
of the costs per LYS that are considered acceptable.18 Therefore, we
recommend switching to Erwinia asparaginase after a hypersensitivity
reaction to PEGasparaginase, apart from a clinical perspective, also
from a cost perspective.
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